Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Non-randomized, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

NCT04742153 is registered in ClinicalTrials.gov with Shanghai Miracogen Inc. as lead sponsor.

NCT NCT04742153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Non-randomized, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
Lead sponsor
Shanghai Miracogen Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
May 13, 2021
Completion date
February 28, 2023
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic breast cancer